Key facts
- ScandiEdge Therapeutics’s last known valuation is $5.5M (Dec 2018).
- It has raised $550K; the latest was Later Stage VC in Jan 2026.
- Notable investors include Navigare Ventures.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for ScandiEdge Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for ScandiEdge Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ScandiEdge Therapeutics
Developer of small-molecule therapeutics intended to address metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma. The company offers enzyme-targeting inhibitors that modulate liver metabolism, reduce fat accumulation, and improve disease outcomes through research-driven approaches originating from Swedish academic institutions, enabling healthcare providers and patients affected by chronic liver conditions to access scientifically validated drug candidates with the potential to improve clinical management and long-term health.
- Sector
- Healthcare
- HQ
- Stockholm, Sweden
- Founded
- 2017
- Employees
- 2
- Ownership
- Privately Held (backing)
ScandiEdge Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ScandiEdge Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ScandiEdge Therapeutics in its N-PORT filings yet. We sweep new filings monthly.